Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 10/20 | 0.51 |
| ▸ | APAF1 | O14727 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CASP3 | P42574 | 5/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 5/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 4/20 | 0.51 |
| ▸ | UBA2 | Q9UBT2 | 4/20 | 0.51 |
| ▸ | THRB | P10828 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | UBE2I | P63279 | 2/20 | 0.51 |
| ▸ | GALK1 | P51570 | 1/20 | 0.51 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844316 | 0.75 | LOXL2 (0.61) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL5311576 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL29488099 | 0.75 | KDM4E (1.00) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL824574 | 0.75 | KDM4E (1.00) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL29784203 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL1687342 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL150458 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL1818129 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL1719778 | 0.75 | LOXL2 (0.61) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL25911541 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | KDM4E 3396/4885GAA 27/4885LOXL2 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.